ATAD1 and malaria: SUM-101, as a candidate malaria vaccine, consists of full-length recombinant PfMSP1 (MSP1FL) (1720 amino acids) derived from the 3D7 strain, manufactured recombinantly in E. coli as a “heterodimer” composed of two peptide chains corresponding to the N- and C-terminal fragments of MSP1, namely p83/30 and p38/42, respectively.6